Annual EBITDA
-$121.21 M
-$7000.00-0.01%
December 31, 2023
Summary
- As of February 8, 2025, IPSC annual EBITDA is -$121.21 million, with the most recent change of -$7000.00 (-0.01%) on December 31, 2023.
- During the last 3 years, IPSC annual EBITDA has fallen by -$69.32 million (-133.61%).
- IPSC annual EBITDA is now -133.61% below its all-time high of -$51.88 million, reached on December 31, 2020.
Performance
IPSC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$27.94 M
-$213.00 K-0.77%
September 30, 2024
Summary
- As of February 8, 2025, IPSC quarterly EBITDA is -$27.94 million, with the most recent change of -$213.00 thousand (-0.77%) on September 30, 2024.
- Over the past year, IPSC quarterly EBITDA has increased by +$842.00 thousand (+2.93%).
- IPSC quarterly EBITDA is now -194.90% below its all-time high of -$9.47 million, reached on March 31, 2020.
Performance
IPSC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$117.21 M
+$842.00 K+0.71%
September 30, 2024
Summary
- As of February 8, 2025, IPSC TTM EBITDA is -$117.21 million, with the most recent change of +$842.00 thousand (+0.71%) on September 30, 2024.
- Over the past year, IPSC TTM EBITDA has dropped by -$4.26 million (-3.77%).
- IPSC TTM EBITDA is now -1137.30% below its all-time high of -$9.47 million, reached on March 31, 2020.
Performance
IPSC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
IPSC EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -0.0% | +2.9% | -3.8% |
3 y3 years | -133.6% | +3.6% | -4.8% |
5 y5 years | +50.4% | +3.6% | -4.8% |
IPSC EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -33.1% | at low | -12.5% | +23.9% | -28.7% | +3.3% |
5 y | 5-year | -133.6% | +50.4% | -194.9% | +23.9% | -1137.3% | +3.3% |
alltime | all time | -133.6% | +50.4% | -194.9% | +23.9% | -1137.3% | +3.3% |
Century Therapeutics EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$27.94 M(+0.8%) | -$117.21 M(-0.7%) |
Jun 2024 | - | -$27.72 M(+11.6%) | -$118.05 M(-1.0%) |
Mar 2024 | - | -$24.84 M(-32.4%) | -$119.30 M(-1.6%) |
Dec 2023 | -$121.21 M(+0.0%) | -$36.72 M(+27.6%) | -$121.26 M(+7.4%) |
Sep 2023 | - | -$28.78 M(-0.7%) | -$112.95 M(+1.0%) |
Jun 2023 | - | -$28.97 M(+8.1%) | -$111.82 M(-0.1%) |
Mar 2023 | - | -$26.80 M(-5.6%) | -$111.90 M(-7.7%) |
Dec 2022 | -$121.20 M | -$28.40 M(+2.7%) | -$121.20 M(+1.3%) |
Sep 2022 | - | -$27.65 M(-4.8%) | -$119.66 M(+2.5%) |
Jun 2022 | - | -$29.05 M(-19.5%) | -$116.72 M(+6.3%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | -$36.10 M(+34.4%) | -$109.77 M(+20.5%) |
Dec 2021 | -$91.06 M(+75.5%) | -$26.86 M(+8.6%) | -$91.06 M(+15.3%) |
Sep 2021 | - | -$24.72 M(+11.9%) | -$78.98 M(+18.1%) |
Jun 2021 | - | -$22.10 M(+27.1%) | -$66.88 M(+11.8%) |
Mar 2021 | - | -$17.39 M(+17.7%) | -$59.80 M(+15.3%) |
Dec 2020 | -$51.88 M(-78.8%) | -$14.78 M(+17.1%) | -$51.88 M(+39.8%) |
Sep 2020 | - | -$12.62 M(-16.0%) | -$37.11 M(+51.5%) |
Jun 2020 | - | -$15.02 M(+58.5%) | -$24.49 M(+158.5%) |
Mar 2020 | - | -$9.47 M | -$9.47 M |
Dec 2019 | -$244.52 M | - | - |
FAQ
- What is Century Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Century Therapeutics?
- What is Century Therapeutics annual EBITDA year-on-year change?
- What is Century Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Century Therapeutics?
- What is Century Therapeutics quarterly EBITDA year-on-year change?
- What is Century Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Century Therapeutics?
- What is Century Therapeutics TTM EBITDA year-on-year change?
What is Century Therapeutics annual EBITDA?
The current annual EBITDA of IPSC is -$121.21 M
What is the all time high annual EBITDA for Century Therapeutics?
Century Therapeutics all-time high annual EBITDA is -$51.88 M
What is Century Therapeutics annual EBITDA year-on-year change?
Over the past year, IPSC annual EBITDA has changed by -$7000.00 (-0.01%)
What is Century Therapeutics quarterly EBITDA?
The current quarterly EBITDA of IPSC is -$27.94 M
What is the all time high quarterly EBITDA for Century Therapeutics?
Century Therapeutics all-time high quarterly EBITDA is -$9.47 M
What is Century Therapeutics quarterly EBITDA year-on-year change?
Over the past year, IPSC quarterly EBITDA has changed by +$842.00 K (+2.93%)
What is Century Therapeutics TTM EBITDA?
The current TTM EBITDA of IPSC is -$117.21 M
What is the all time high TTM EBITDA for Century Therapeutics?
Century Therapeutics all-time high TTM EBITDA is -$9.47 M
What is Century Therapeutics TTM EBITDA year-on-year change?
Over the past year, IPSC TTM EBITDA has changed by -$4.26 M (-3.77%)